Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||DFF332 + Spartalizumab + Taminadenant|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|DFF332||DFF 332|DFF-332||HIF2A Inhibitor 6||DFF332 inhibits HIF-2alpha and blocks its DNA binding, which may lead to downregulation of HIF-2alpha target genes involved in tumor cell growth and survival (NCI Drug Dictionary).|
|Spartalizumab||PDR001|PDR-001||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 112||Spartalizumab (PDR001) is a monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (PMID: 32364844, PMID: 32179633).|
|Taminadenant||NIR178|PBF-509||Adenosine Targeting 23||Taminadenant binds to and inhibits the adenosine A2A (ADORA2A) receptor on immune cells, resulting in activation of an anti-tumor immune response by blocking binding of the immunosuppressive metabolite, adenosine (PMID: 29758241, PMID: 28582704).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04895748||Phase I||DFF332 + Spartalizumab + Taminadenant DFF332 + Everolimus DFF332||DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies||Recruiting||USA | ITA | FRA | ESP||3|